Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boyan K Garvalov

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Science (New York, N.Y.)|October 23, 2004
Struggling to attend U.S. meetingsBoyan K Garvalov
Nature|January 18, 2013
Sexism: Measure journal objectivityBoyan K Garvalov
EMBO Reports|May 2, 2007
Mobility is not the only way forwardBoyan K Garvalov
Nature|March 7, 2008
Who stands to lose from double-blind review?Boyan K Garvalov
Journal of Molecular Medicine (Berlin, Germany)|October 5, 2010
Cancer stem cells: a new framework for the design of tumor therapiesBoyan K Garvalov, Till Acker
Nature Biomedical Engineering|April 25, 2019
Seeing whole-tumour heterogeneityBoyan K Garvalov, Ali Ertürk
Advances in Experimental Medicine and Biology|June 26, 2016
Implications of Oxygen Homeostasis for Tumor Biology and TreatmentBoyan K Garvalov, Till Acker
Aging|September 22, 2019
Lamin B1 in cancer and agingBoyan K Garvalov, Sajjad Muhammad, Gergana Dobreva
Methods in Molecular Biology (Clifton, N.J.)|November 13, 2014
Isolation and culture of primary glioblastoma cells from human tumor specimensSascha Seidel, Boyan K Garvalov, Till Acker
Biochimica Et Biophysica Acta|October 20, 2012
The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironmentAlina Filatova, Till Acker, Boyan K Garvalov
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Science (New York, N.Y.)|October 23, 2004
Struggling to attend U.S. meetingsBoyan K Garvalov
Nature|January 18, 2013
Sexism: Measure journal objectivityBoyan K Garvalov
EMBO Reports|May 2, 2007
Mobility is not the only way forwardBoyan K Garvalov
Nature|March 7, 2008
Who stands to lose from double-blind review?Boyan K Garvalov
Journal of Molecular Medicine (Berlin, Germany)|October 5, 2010
Cancer stem cells: a new framework for the design of tumor therapiesBoyan K Garvalov, Till Acker
Nature Biomedical Engineering|April 25, 2019
Seeing whole-tumour heterogeneityBoyan K Garvalov, Ali Ertürk
Advances in Experimental Medicine and Biology|June 26, 2016
Implications of Oxygen Homeostasis for Tumor Biology and TreatmentBoyan K Garvalov, Till Acker
Aging|September 22, 2019
Lamin B1 in cancer and agingBoyan K Garvalov, Sajjad Muhammad, Gergana Dobreva
Methods in Molecular Biology (Clifton, N.J.)|November 13, 2014
Isolation and culture of primary glioblastoma cells from human tumor specimensSascha Seidel, Boyan K Garvalov, Till Acker
Biochimica Et Biophysica Acta|October 20, 2012
The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironmentAlina Filatova, Till Acker, Boyan K Garvalov
Pageof 5